Presentation THT 2025 Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF) Presenter: Jonathan Zawadzki February 12, 2025
Presentation THT Abstracts 2025 Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector Presenter: John Mohr February 11, 2025
Presentation THT Abstracts 2025 Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis Presenter: Stavros Drakos February 11, 2025
Presentation THT 2025 Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector Presenter: John Mohr February 11, 2025
Presentation THT 2025 Emerging Therapies Targeting Inflammation and Metabolic Dysfunction in Heart Failure Presenter: Mark Petrie February 11, 2025
News Daily News Societies Update Appropriate Use Criteria for Cardiac Implantable Devices Todd Neale January 23, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025
News Daily News Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3 Yael L. Maxwell January 15, 2025
News Daily News Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit Michael O'Riordan January 13, 2025
News Opinion Editor's Corner TCTMD’s Biggest News of 2024: Stories, Videos, and More Shelley Wood January 01, 2025
News Daily News FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity L.A. McKeown December 13, 2024
News Daily News Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More Michael O'Riordan December 06, 2024